Advertisement

Keywords

Multiple Myeloma Programme Cell Death Proteasome Inhibitor Mantle Cell Lymphoma Liposomal Doxorubicin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

9. References

  1. Aberle H, Bauer A, Stappert J, et al., (1997). Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J, 16:3797–804.PubMedGoogle Scholar
  2. Adams J. (2002). Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol, 14:628–34.PubMedGoogle Scholar
  3. Adams J, Palombella VJ, Sausville EA, et al., (1999). Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res, 59:2615–22.PubMedGoogle Scholar
  4. Aghajanian C, Dizon D, Yan XJ, et al., (2003). Phase I trial of PS-341 and carboplatin in recurrent ovarian cancer. Proc Amer Soc Clin Oncol, 22:452, Abstract 1815.Google Scholar
  5. Aghajanian C, Soignet S, Dizon DS, et al., (2002). A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res, 8:2505–11.PubMedGoogle Scholar
  6. An B, Goldfarb RH, Siman R & Dou QP. (1998). Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ, 5:1062–75.PubMedGoogle Scholar
  7. Barlogie B, Shaughnessy JD, Tricot G, et al., (2004). Treatment of multiple myeloma. Blood, 103:20–32.PubMedGoogle Scholar
  8. Basu A, Das M, Qanungo S, et al., (2002). Proteasomal degradation of human peptidyl-prolyl-isomerase Pin-1-pointing phospho-Bcl-2 toward dephosphorylation. Neoplasia, 4:218–27.PubMedGoogle Scholar
  9. Bellamy WT, Odeleye A, Huizenga E, et al., (1995). Severe combined immunodeficiency mouse modeling of P-glycoprotein chemosensitization in multi-drug-resistant human myeloma xenografts. Clin Cancer Res, 1:1563–70.PubMedGoogle Scholar
  10. Berti R, Williams AJ, Velarde LC, et al., (2003). Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat. Neurotox Res, 5:505–14.PubMedGoogle Scholar
  11. Bladé J, Samson D, Reece D, et al., (1998). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the European Group for Blood and Marrow Transplant. Br J Haematol, 102:1115–23.PubMedGoogle Scholar
  12. Blagosklonny MV, Wu GS, Omura S & el-Deiry WS. (1996). Proteasome-dependent regulation of p21Wafl/Cipl expression. Biochem Biophys Res Commun, 227:564–9.PubMedGoogle Scholar
  13. Bloom J & Pagano M. (2003). Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol, 13:41–7.PubMedGoogle Scholar
  14. Bonni A, Brunet A, West AE, et al., (1999). Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and-independent mechanisms. Science, 286:1358–62.PubMedGoogle Scholar
  15. Bosland M. (2003). Bombesin stimulates nuclear factor kappa B activation and expression of pro-angiogenic factors in prostate cancer cells. Urol Oncol, 21:415.Google Scholar
  16. Breitschopf K, Zeiher AM & Dimmeler S. (2000). Ubiquitin-mediated degradation of the pro-apoptotic active form of Bid. A functional consequence on apoptosis induction. J Biol Chem, 275:21648–52.PubMedGoogle Scholar
  17. Campbell B, Adams J, Shin YK & Lefer AM. (1999). Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol, 31:467–76.PubMedGoogle Scholar
  18. Cayrol C & Ducommun B. (1998). Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene, 17:2437–44.PubMedGoogle Scholar
  19. Chang F, Steelman LS, Shelton JG, et al., (2003). Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol, 22:469–80.PubMedGoogle Scholar
  20. Chang YC, Lee YS, Tejima T, et al., (1998). Mdm2 and Bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ, 9:79–84.PubMedGoogle Scholar
  21. Chauhan D, Li G, Hideshima T, et al., (2003a). HSP-27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood, 102:3379–86.PubMedGoogle Scholar
  22. Chauhan D, Li G, Hideshima T, et al., (2003b). JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma cells. J Biol Chem, 278:17593–6.PubMedGoogle Scholar
  23. Chauhan D, Li G, Shringarpure R, Podar K, et al., (2003c). Blockade of HSP-27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res, 63:6174–7.PubMedGoogle Scholar
  24. Chauhan D, Uchiyama H, Akbarali Y, et al., (1996). Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood, 87:1104–12.PubMedGoogle Scholar
  25. Chiarle R, Budel LM, Skolnik J, et al., (2000). Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood, 95:619–26.PubMedGoogle Scholar
  26. Ciechanover A, Orian A & Schwartz AL. (2000). Ubiquitin-mediated proteolysis: Biological regulation via destruction. Bioessays, 22:442–51.PubMedGoogle Scholar
  27. Cobb RR, Felts KA, Parry GC, et al., (1996). Proteasome inhibitors block VCAM-1 and ICAM-1 gene expression in endothelial cells without affecting nuclear translocation of nuclear factor-kappa B. Eur J Immunol, 26:839–45.PubMedGoogle Scholar
  28. Cusack JC Jr, Liu R, Houston M, et al., (2001). Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res, 61:3535–40.PubMedGoogle Scholar
  29. Dagia NM and Goetz DJ. (2003). A proteasome inhibitor reduces concurrent, sequential, and long-term IL-1 beta-and TNF-alpha-induced ECAM expression and adhesion. Am J Physiol Cell Physiol, 285:C813–C822.PubMedGoogle Scholar
  30. Davies KJ. (2001). Degradation of oxidized proteins by the 20S proteasome. Biochimie, 83:301–10.PubMedGoogle Scholar
  31. Davis NB, Taber DA, Ansari RH, et al., (2004). Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study. J Clin Oncol, 22:115–19.PubMedGoogle Scholar
  32. Dees EC, O’Neil B, Humes E, et al., (2003). Phase I trial of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory solid tumors. Proc American Soc Clin Oncol, 22:217, Abstract 868.Google Scholar
  33. DeMartino GN & Slaughter CA. (1999). The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem, 274:22123–6.PubMedGoogle Scholar
  34. Desai SD, Li TK, Rodriguez-Bauman A, et al., (2001). Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res, 61:5926–32.PubMedGoogle Scholar
  35. Desai SD, Liu LF, Vazquez-Abad D, et al., (1997). Ubiquitin-dependent destruction of topoisomerase I is stimulated by the anti-tumor drug camptothecin. J Biol Chem, 272:24159–64.PubMedGoogle Scholar
  36. Di Napoli M & Papa F. (2003). The proteasome system and proteasome inhibitors in stroke: Controlling the inflammatory response. Curr Opin Investig Drugs, 4:1333–42.PubMedGoogle Scholar
  37. Drexler HC. (1997). Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA, 94:855–60.PubMedGoogle Scholar
  38. Drexler HC. (2003). The role of p27Kipl in proteasome inhibitor induced apoptosis. Cell Cycle, 2:438–41.PubMedGoogle Scholar
  39. Drexler HC & Pebler S. (2003). Inducible p27Kipl expression inhibits proliferation of K562 cells and protects against apoptosis induction by proteasome inhibitors. Cell Death Differ, 10:290–301.PubMedGoogle Scholar
  40. El-Shami KM, Tirosh B, Popovic D, et al., (2000). Induction of anti-tumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide. Int J Cancer, 85:236–42.PubMedGoogle Scholar
  41. Elliott PJ, Zollner TM & Boehncke WH. (2003). Proteasome inhibition: A new anti-inflammatory strategy. J Mol Med, 81:235–45.PubMedGoogle Scholar
  42. Filipits M, Pohl G, Stranzl T, et al., (2003). Low p27Kipl expression is an independent adverse prognostic factor in patients with multiple myeloma. Clin Cancer Res, 9:820–6.PubMedGoogle Scholar
  43. Frankel A, Man S, Elliott P, et al., (2000). Lack of multi-cellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res, 6:3719–28.PubMedGoogle Scholar
  44. Fredersdorf S, Burns J, Milne AM, et al., (1997). High level expression of p27Kipl and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27Kipl and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA, 94:6380–5.PubMedGoogle Scholar
  45. Garrido C, Bruey JM, Fromentin A, et al., (1999). HSP-27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J, 13:2061–70.PubMedGoogle Scholar
  46. Giuliani N, Lunghi P, Morandi F, et al., (2004). Down-modulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia, 18:628–35.PubMedGoogle Scholar
  47. Golab J, Stoklosa T, Czajka A, et al., (2000). Synergistic anti-tumor effects of a selective proteasome inhibitor and TNF in mice. Anticancer Res, 20:1717–21.PubMedGoogle Scholar
  48. Gonen H, Shkedy D, Barnoy S, et al., (1997). On the involvement of calpains in the degradation of the tumor suppressor protein p53. FEBS Lett, 406:17–22.PubMedGoogle Scholar
  49. Goy A, Hart S, Pro B, et al., (2003). Report of a phase II study of proteasome inhibitor bortezomib (VELCADE®) in patients with relapsed or refractory indolent or aggressive lymphomas. Blood, 102:180a, Abstract 627.Google Scholar
  50. Gregory RC, Taniguchi T & D’Andrea AD. (2003). Regulation of the Fanconi anemia pathway by monoubiquitination. Semin Cancer Biol, 13:77–82.PubMedGoogle Scholar
  51. Guo YL, Baysal K, Kang B, et al., (1998a). Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor-alpha in rat mesangial cells. J Biol Chem, 273:4027–34.PubMedGoogle Scholar
  52. Guo YL, Kang B & Williamson JR. (1998b). Inhibition of the expression of mitogen-activated protein kinase phosphatase-1 potentiates apoptosis induced by tumor necrosis factor-alpha in rat mesangial cells. J Biol Chem, 273:10362–6.PubMedGoogle Scholar
  53. Guzman ML, Swiderski CF, Howard DS, et al., (2002). Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA, 99:16220–5.PubMedGoogle Scholar
  54. Haglund K, Di Fiore PP & Dikic I. (2003). Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem Sci, 28:598–603.PubMedGoogle Scholar
  55. Hashizume R, Fukuda M, Maeda I, et al., (2001). The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem, 276:14537–40.PubMedGoogle Scholar
  56. He Q, Huang Y & Sheikh MS. (2004). Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and-deficient cells. Oncogene, 23:2554–8.PubMedGoogle Scholar
  57. Herrmann JL, Briones F Jr., Brisbay S, et al., (1998). Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene, 17:2889–99.PubMedGoogle Scholar
  58. Hershko A. (1997). Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol, 9:788–99.PubMedGoogle Scholar
  59. Hideshima T, Chauhan D, Hayashi T, et al., (2003). Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent down-regulation of gp130 in multiple myeloma. Oncogene, 22:8386–93.PubMedGoogle Scholar
  60. Hideshima T, Chauhan D, Schlossman R, et al., (2001a). The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene, 20:4519–27.PubMedGoogle Scholar
  61. Hideshima T, Richardson P, Chauhan D, et al., (2001b). The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res, 61:3071–3076.PubMedGoogle Scholar
  62. Honda R, Tanaka H & Yasuda H. (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett, 420:25–7.PubMedGoogle Scholar
  63. Imajoh-Ohmi KT, Sugiyama S, Tanaka K, et al., (1995). Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun, 217:1070–7.PubMedGoogle Scholar
  64. Ishibashi T, Shinogami M, Ishimoto S, et al., (2001). Identification of dual specificity phosphatases induced by olfactory bulbectomy in rat olfactory neuroepithelium. Brain Res, 902:205–11.PubMedGoogle Scholar
  65. Jagannath S, Durie BGM, Wolf J, et al., (2003). Bortezomib (VELCADE®, formerly PS-341) as first-line therapy in patients with multiple myeloma. Blood, 102:452a, Abstract 1650.Google Scholar
  66. Jan MS, Liu HS & Lin YS. (1999). Bad overexpression sensitizes NIH/3T3 cells to undergo apoptosis which involves caspase activation and ERK inactivation. Biochem Biophys Res Commun, 264:724–9.PubMedGoogle Scholar
  67. Jobin C, Hellerbrand C, Licato LL, et al., (1998). Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 in an intestinal epithelial cell line, a process blocked by proteasome inhibitors. Gut, 42:779–87.PubMedGoogle Scholar
  68. Johnson GL & Lapadat R. (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298:1911–2.PubMedGoogle Scholar
  69. Johnson TR, Stone K, Nikrad M, et al., (2003). The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-Xl overexpressing cells. Oncogene, 22:4953–63.PubMedGoogle Scholar
  70. Kalogeris TJ, Kevil CG, Laroux FS, et al., (1999). Differential monocyte adhesion and adhesion molecule expression in venous and arterial endothelial cells. Am J Physiol, 276:L9–L19.PubMedGoogle Scholar
  71. Katagiri K, Yokosawa H, Kinashi T, et al., (1999). Ubiquitin-proteasome system is involved in induction of LFA-1/ICAM-1-dependent adhesion of HL-60 cells. J Leukoc Biol, 65:778–85.PubMedGoogle Scholar
  72. Kirkin V, Joos S & Zornig M. (2004). The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta, 1644:229–49.PubMedGoogle Scholar
  73. Kisselev AF & Goldberg AL. (2001). Proteasome inhibitors: From research tools to drug candidates. Chem Biol, 8:739–58.PubMedGoogle Scholar
  74. Kloetzel PM. (2001). Antigen processing by the proteasome. Nat Rev Mol Cell Biol, 2:179–87.PubMedGoogle Scholar
  75. Kubbutat MH & Vousden KH. (1997). Proteolytic cleavage of human p53 by calpain: A potential regulator of protein stability. Mol Cell Biol, 17:460–8.PubMedGoogle Scholar
  76. Kudo Y, Takata T, Ogawa I, et al., (2000). p27Kipl accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res, 6:916–23.PubMedGoogle Scholar
  77. Kumeda SI, Deguchi A, Toi M, et al., (1999). Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells. Anticancer Res, 19:3961–8.PubMedGoogle Scholar
  78. Laiho M & Latonen L. (2003). Cell cycle control, DNA damage checkpoints and cancer. Ann Med, 35:391–7.PubMedGoogle Scholar
  79. LeBlanc R, Catley LP, Hideshima T, et al., (2002). Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res, 62:4996–5000.PubMedGoogle Scholar
  80. Leonard GD, Fojo T & Bates SE. (2003). The role of ABC transporters in clinical practice. Oncologist, 8:411–24.PubMedGoogle Scholar
  81. Levine L, Lucci JA, Pazdrak, B, et al., (2003). Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res, 63:3495–502.PubMedGoogle Scholar
  82. Li B & Dou QP. (2000). Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression. Proc Natl Acad Sci USA, 97:3850–5.PubMedGoogle Scholar
  83. Li H, Zhu H, Xu CJ, et al., (1998). Cleavage of Bid by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 94:491–501.PubMedGoogle Scholar
  84. Lightcap ES, McCormack TA, Pien CS, et al., (2000). Proteasome inhibition measurements: Clinical application. Clin Chem, 46:673–83.PubMedGoogle Scholar
  85. Lin A & Karin M. (2003). NF-kappaB in cancer: A marked target. Semin Cancer Biol, 13:107–114.PubMedGoogle Scholar
  86. Lin JH & Yamazaki M. (2003). Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev, 35:417–54.PubMedGoogle Scholar
  87. Ling YH, Liebes L, Ng B, et al., (2002). PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther, 1:841–9.PubMedGoogle Scholar
  88. Loo TW & Clarke DM. (1998). Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions. J Biol Chem, 273:14671–4.PubMedGoogle Scholar
  89. Loo TW & Clarke DM. (1999). The human multi-drug resistance P-glycoprotein is inactive when its maturation is inhibited: Potential for a role in cancer chemotherapy. FASEB J, 13:1724–32.PubMedGoogle Scholar
  90. Lopes UG, Erhardt P, Yao R, et al., (1997). p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem, 272:12893–6.PubMedGoogle Scholar
  91. Luciano F, Jacquel A, Colosetti P, et al., (2003). Phosphorylation of Bim-El by ERK-1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its pro-apoptotic function. Oncogene, 22:6785–93.PubMedGoogle Scholar
  92. Ma MH, Yang HH, Parker K, et al., (2003). The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res, 9:1136–44.PubMedGoogle Scholar
  93. MacFarlane M, Merrison W, Bratton SB & Cohen GM. (2002). Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem, 277:36611–16.PubMedGoogle Scholar
  94. MacKeigan JP, Collins TS & Ting JP. (2000). MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem, 275:38953–6.PubMedGoogle Scholar
  95. Maloney A & Workman P. (2002). HSP-90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther, 2:3–24.PubMedGoogle Scholar
  96. Marschitz I, Lechner J, Mosser I, et al., (2000). Differential expression of cell-cell adhesion proteins and cyclin D in MEK 1-transdifferentiated MDCK cells. Am J Physiol Cell Physiol, 279:C1472–C1482.PubMedGoogle Scholar
  97. Masdehors P, Omura S, Merle-Beral H, et al., (1999). Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol, 105:752–7.PubMedGoogle Scholar
  98. Mehlen P, Schulze-Osthoff K & Arrigo AP. (1996). Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/APO-1-and staurosporine-induced cell death. J Biol Chem, 271:16510–14.PubMedGoogle Scholar
  99. Meriin AB, Gabai VL, Yaglom J, et al., (1998). Proteasome inhibitors activate stress kinases and induce HSP-72. Diverse effects on apoptosis. J Biol Chem, 273:6373–9.PubMedGoogle Scholar
  100. Mezquita J, Mezquita B, Pau M & Mezquita C. (2003). Down-regulation of Flt-1 gene expression by the proteasome inhibitor MG262. J Cell Biochem, 89:1138–47.PubMedGoogle Scholar
  101. Mitsiades N, Mitsiades CS, Poulaki V, et al., (2002a). Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA, 99:14374–9.PubMedGoogle Scholar
  102. Mitsiades N, Mitsiades CS, Poulaki V et al., (2002b). Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications. Blood, 99:4079–86.PubMedGoogle Scholar
  103. Mitsiades N, Mitsiades CS, Richardson PG, et al., (2003). The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood, 101:2377–80.PubMedGoogle Scholar
  104. Mosser DD, Caron AW, Bourget L, et al., (2000). The chaperone function of HSP-70 is required for protection against stress-induced apoptosis. Mol Cell Biol, 20:7146–59.PubMedGoogle Scholar
  105. Murakami Y, Matsufuji S, Kameji T, et al., (1992). Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature, 360:597–9.PubMedGoogle Scholar
  106. Murray AW. (2004). Recycling the cell cycle: Cyclins revisited. Cell, 116:221–34.PubMedGoogle Scholar
  107. Nakano K & Vousden KH. (2001). PUMA, a novel pro-apoptotic gene, is induced by p53. Mol Cell, 7:683–94.PubMedGoogle Scholar
  108. Nawrocki ST, Bruns CJ, Harbison MT, et al., (2002). Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther, 1:1243–53.PubMedGoogle Scholar
  109. Nawrocki ST, Sweeney-Gotsch B, Takamori R & McConkey DJ. (2004). The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther, 3:59–70.PubMedGoogle Scholar
  110. Neckers L (2002). HSP-90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med, 8:S55–S61.PubMedGoogle Scholar
  111. Nho RS & Sheaff RJ. (2003). p27Kipl contributions to cancer. Prog Cell Cycle Res, 5:249–59.PubMedGoogle Scholar
  112. O’Connor O, Wright J, Moskowitz CH, et al., (2003). Promising activity of the proteasome inhibitor bortezomib (VELCADE®) in the treatment of indolent non-Hodgkins lymphoma and mantle cell lymphoma. Blood, 102:636a, Abstract 2346.Google Scholar
  113. Oda E, Ohki R, Murasawa H, et al., (2000). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science, 288:1053–8.PubMedGoogle Scholar
  114. Ogiso Y, Tomida A, Lei S, et al.,(2000). Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res, 60:2429–34.PubMedGoogle Scholar
  115. Ohki R, Nemoto J, Murasawa H, et al., (2000). Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem, 275:22627–30.PubMedGoogle Scholar
  116. Oikawa T, Sasaki T, Nakamura M, et al., (1998). The proteasome is involved in angiogenesis. Biochem Biophys Res Commun, 246:243–8.PubMedGoogle Scholar
  117. Orlowski M & Wilk S. (2000). Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys, 383:1–16.PubMedGoogle Scholar
  118. Orlowski RZ. (1999). The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ, 6:303–13.PubMedGoogle Scholar
  119. Orlowski RZ. (2004). Bortezomib and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther, 4:171–9.PubMedGoogle Scholar
  120. Orlowski RZ & Baldwin AS. (2002). NF-kappaB as a therapeutic target in cancer. Trends Mol Med, 8:385–9.PubMedGoogle Scholar
  121. Orlowski RZ, Eswara JR, Lafond-Walker A, et al., (1998). Tumor growth inhibition induced in a murine model of human Burkitt’s lymphoma by a proteasome inhibitor. Cancer Res, 58:4342–8.PubMedGoogle Scholar
  122. Orlowski RZ, Small GW & Shi YY. (2002a). Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem, 277:27864–71.PubMedGoogle Scholar
  123. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al., (2002b). Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol, 20:4420–7.PubMedGoogle Scholar
  124. Orlowski RZ, Voorhees PM, Garcia RA, et al., (2003). Phase I study of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Blood, 102:449a, Abstract 1639.Google Scholar
  125. Palombella VJ, Conner EM, Fuseler JW, et al., (1998). Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA, 95:15671–6.PubMedGoogle Scholar
  126. Palombella VJ, Rando OJ, Goldberg AL & Maniatis T. (1994). The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell, 78:773–85.PubMedGoogle Scholar
  127. Pariat M, Carillo S, Molinari M, et al., (1997). Proteolysis by calpains: A possible contribution to degradation of p53. Mol Cell Biol, 17:2806–15.PubMedGoogle Scholar
  128. Park BK, Zeng X & Glazer RI. (2001). Aktl induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res, 61:7647–53.PubMedGoogle Scholar
  129. Pei XY, Dai Y & Grant S. (2003). The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia, 17:2036–45.PubMedGoogle Scholar
  130. Pommier Y, Sordet O, Antony S, et al., (2004). Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene, 23:2934–49.PubMedGoogle Scholar
  131. Porter PL, Malone KE, Heagerty PJ, et al., (1997). Expression of cell-cycle regulators p27Kipl and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med, 3:222–5.PubMedGoogle Scholar
  132. Putcha GV, Le S, Frank S, et al., (2003). JNK-mediated Bim phosphorylation potentiates Bax-dependent apoptosis. Neuron, 38:899–914.PubMedGoogle Scholar
  133. Reddy KB, Nabha SM & Atanaskova N. (2003). Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev, 22:395–403.PubMedGoogle Scholar
  134. Richardson PG, Barlogie B, Berenson J, et al., (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 348:2609–17.PubMedGoogle Scholar
  135. Robertson JD, Datta K, Biswal SS & Kehrer JP. (1999). Heat-shock protein 70 antisense oligomers enhance proteasome inhibitor-induced apoptosis. Biochem J, 344 Pt 2:477–85.PubMedGoogle Scholar
  136. Rock KL, Gramm C, Rothstein L, et al., (1994). Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 78:761–71.PubMedGoogle Scholar
  137. Rock KL, York IA, Saric T & Goldberg AL. (2002). Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol, 80:1–70.PubMedGoogle Scholar
  138. Rolfe M, Beer-Romero P, Glass, S, et al., (1995). Reconstitution of p53-ubiquitinylation reactions from purified components: The role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein. Proc Natl Acad Sci USA, 92:3264–8.PubMedGoogle Scholar
  139. Salvat C, Aquaviva C, Jariel-Encontre I, et al., (1999). Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo? Mol Biol Rep, 26:45–51.PubMedGoogle Scholar
  140. Santen RJ, Song RX, McPherson R, et al., (2002). The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol, 80:239–56.PubMedGoogle Scholar
  141. Sayers TJ, Brooks AD, Koh CY, et al., (2003). The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood, 102:303–10.PubMedGoogle Scholar
  142. Scheffner M, Huibregtse JM, Vierstra RD & Howley PM. (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell, 75:495–505.PubMedGoogle Scholar
  143. Scheid MP, Schubert KM & Duronio V. (1999). Regulation of Bad phosphorylation and association with Bcl-xl by the MAPK/ERK kinase. J Biol Chem, 274:31108–13.PubMedGoogle Scholar
  144. Shibata A, Nagaya T, Imai T, et al., (2002). Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat, 73:237–43.PubMedGoogle Scholar
  145. Shinohara K, Tomioka M, Nakano H, et al., (1996). Apoptosis induction resulting from proteasome inhibition. Biochem J, 317:385–8.PubMedGoogle Scholar
  146. Shirane M, Harumiya Y, Ishida N, et al., (1999). Down-regulation of p27Kipl by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem, 274:13886–93.PubMedGoogle Scholar
  147. Shmueli A & Oren M. (2004). Regulation of p53 by Mdm2: Fate is in the numbers. Mol Cell, 13:4–5.PubMedGoogle Scholar
  148. Signoretti S, Di Marcotullio L, Richardson A, et al., (2002). Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest, 110:633–41.PubMedGoogle Scholar
  149. Slee EA, O’Connor DJ & Lu X. (2004). To die or not to die: How does p53 decide? Oncogene, 23:2809–18.PubMedGoogle Scholar
  150. Small GW, Somasundaram S, Moore DT, et al., (2003). Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their anti-apoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther, 307:861–9.PubMedGoogle Scholar
  151. Stearns ME, Wang M, Hu Y & Garcia FU. (2003). Interleukin-10 activation of the interleukin-10E1 pathway and tissue inhibitor of metalloproteinase-1 expression is enhanced by proteasome inhibitors in primary prostate tumor lines. Mol Cancer Res, 1:631–42.PubMedGoogle Scholar
  152. Stoklosa T, Golacedil BJ, Wojcik C, et al., (2004). Increased local vascular endothelial growth factor expression associated with anti-tumor activity of proteasome inhibitor. Apoptosis, 9:193–204.PubMedGoogle Scholar
  153. Sunwoo JB, Chen Z, Dong G, et al., (2001). Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res, 7:1419–28.PubMedGoogle Scholar
  154. Tan P, Cady B, Wanner M, et al., (1997). The cell cycle inhibitor p27 is an independent prognostic marker in small (Tla,b) invasive breast carcinomas. Cancer Res, 57:1259–63.PubMedGoogle Scholar
  155. Tanahashi N, Kawahara H, Murakami Y & Tanaka K. (1999). The proteasome-dependent proteolytic system. Mol Biol Rep, 26:3–9.PubMedGoogle Scholar
  156. Teicher BA, Ara G, Herbst R, et al., (1999). The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res, 5:2638–45.PubMedGoogle Scholar
  157. Tournier C, Hess P, Yang DD, et al., (2000). Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science, 288:870–4.PubMedGoogle Scholar
  158. Tsuruta F, Sunayama J, Mori Y, et al., (2004). JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J, 23:1889–99.PubMedGoogle Scholar
  159. Tsvetkov LM, Yeh KH, Lee SJ, et al., (1999). p27Kipl ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thrl87 in p27. Curr Biol, 9:661–4.PubMedGoogle Scholar
  160. Vinitsky A, Michaud C, Powers JC & Orlowski M. (1992). Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry, 31:9421–8.PubMedGoogle Scholar
  161. Voorhees PM, Dees EC, O’Neil B & Orlowski RZ. (2003). The proteasome as a target for cancer therapy. Clin Cancer Res, 9:6316–25.PubMedGoogle Scholar
  162. Wagenknecht B, Hermisson M, Eitel K & Weller M. (1999). Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. Cell. Physiol Biochem., 9:117–25.PubMedGoogle Scholar
  163. Wang CY, Mayo MW & Baldwin AS Jr. (1996). TNF-and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB. Science, 274:784–7.PubMedGoogle Scholar
  164. Williams S, Pettaway C, Song R, et al., (2003). Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther, 2:835–43.PubMedGoogle Scholar
  165. Williams SA & McConkey DJ. (2003). The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res, 63:7338–44.PubMedGoogle Scholar
  166. Wong C, Morse M & Nair SK. (1998). Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J Immunother, 21:32–40.PubMedGoogle Scholar
  167. Xia L, Pan J, Yao L & McEver RP. (1998). A proteasome inhibitor, an antioxidant, or a salicylate, but not a glucocorticoid, blocks constitutive and cytokine-inducible expression of P-selectin in human endothelial cells. Blood, 91:1625–32.PubMedGoogle Scholar
  168. Yamada Y, Sugahara K, Tsuruda K, et al., (2000). Lactacystin activates FLICE (caspase 8) protease and induces apoptosis in Fas-resistant adult T-cell leukemia cell lines. Eur J Haematol, 64:315–22.PubMedGoogle Scholar
  169. Yang HH, Ma MH, Vescio RA & Berenson JR. (2003). Overcoming drug resistance in multiple myeloma: The emergence of therapeutic approaches to induce apoptosis. J Clin Oncol, 21:4239–47.PubMedGoogle Scholar
  170. You SA, Basu A & Haldar S. (1999). Potent anti-tumor agent proteasome inhibitors: A novel trigger for Bcl-2 phosphorylation to induce apoptosis. Int J Oncol, 15:625–8.PubMedGoogle Scholar
  171. Yu C, Rahmani M, Dent P & Grant S. (2004). The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor bortezomib. Exp Cell Res, 295:555–66.PubMedGoogle Scholar
  172. Zangari M, Barlogie B, Jacobson J, et al., (2003). VTD regimen comprising VELCADE® (V) + thalidomide (T) and added dex (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma relapsing after autologous transplant. Blood, 102:236a, Abstract 830.Google Scholar
  173. Zha J, Harada H, Osipov K, et al., (1997). BH3 domain of Bad is required for heterodimerization with Bcl-xl and pro-apoptotic activity. J Biol Chem, 272:24101–04.PubMedGoogle Scholar
  174. Zhang HG, Wang J, Yang X, et al., (2004). Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene, 23:2009–15.PubMedGoogle Scholar
  175. Zhang W, Lu Q, Xie ZJ & Mellgren RL. (1997). Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr-diazomethyl ketone: Evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition. Oncogene, 14:255–63.PubMedGoogle Scholar
  176. Zhang XM, Lin H, Chen C & Chen BD. (1999). Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells. Biochem J, 340(Pt 1):127–33.PubMedGoogle Scholar
  177. Zhu W, Zou Y, Aikawa R, et al., (1999). MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation, 100:2100–07.PubMedGoogle Scholar
  178. Zwickl P, Baumeister W & Steven A. (2000). Dis-assembly lines: The proteasome and related ATPase-assisted proteases. Curr Opin Struct Biol, 10:242–50.PubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Robert Z. Orlowski
    • 1
  1. 1.22-003 Lineberger Comprehensive Cancer CenterThe University of North CarolinaChapel Hill

Personalised recommendations